Pfizer gets USFDA nod for XALKORI (crizotinib) to treat ALK-positive ALCL in children and young…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.